These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 1387244)

  • 21. Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis.
    Kris MG; Tyson LB; Clark RA; Gralla RJ
    Cancer; 1992 Aug; 70(4 Suppl):1012-6. PubMed ID: 1386282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens.
    Cubeddu LX; Hoffman IS; Fuenmayor NT; Finn AL
    J Clin Oncol; 1990 Oct; 8(10):1721-7. PubMed ID: 2145400
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral ondansetron (GR38032F) for the control of acute and delayed cyclophosphamide-induced emesis.
    Rosso R; Campora E; Cetto G; Fosser V; Marangolo M; Oliva C
    Anticancer Res; 1991; 11(2):937-9. PubMed ID: 1829602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ondansetron and cisplatin-induced nausea and vomiting.
    Hait WN
    N Engl J Med; 1990 Nov; 323(21):1485-6. PubMed ID: 2146502
    [No Abstract]   [Full Text] [Related]  

  • 25. Emesis as a complication of cancer chemotherapy: pathophysiology, importance, and treatment.
    Graves T
    Pharmacotherapy; 1992; 12(4):337-45. PubMed ID: 1387707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Italian Group For Antiemetic Research.
    Lancet; 1992 Jul; 340(8811):96-9. PubMed ID: 1352024
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting.
    Cubeddu LX; Hoffmann IS; Fuenmayor NT; Finn AL
    N Engl J Med; 1990 Mar; 322(12):810-6. PubMed ID: 1689807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy.
    Bloch J; Rixe O; Meric JB; Delgado A; Khayat D
    Curr Med Res Opin; 2005 Nov; 21(11):1763-71. PubMed ID: 16307696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo.
    Gandara DR; Harvey WH; Monaghan GG; Perez EA; Stokes C; Bryson JC; Finn AL; Hesketh PJ
    Semin Oncol; 1992 Aug; 19(4 Suppl 10):67-71. PubMed ID: 1387253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Gastrointestinal toxicity induced by anticancer drugs--including new antiemetic drugs].
    Sampi K; Taguchi T
    Gan To Kagaku Ryoho; 1990 Apr; 17(4 Pt 2):922-8. PubMed ID: 2140498
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.
    Hainsworth J; Harvey W; Pendergrass K; Kasimis B; Oblon D; Monaghan G; Gandara D; Hesketh P; Khojasteh A; Harker G
    J Clin Oncol; 1991 May; 9(5):721-8. PubMed ID: 1826739
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ondansetron in the treatment of theophylline overdose.
    Brown SG; Prentice DA
    Med J Aust; 1992 Apr; 156(7):512. PubMed ID: 1532627
    [No Abstract]   [Full Text] [Related]  

  • 33. Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy.
    Stewart DJ; Dahrouge S; Coyle D; Evans WK
    J Clin Oncol; 1999 Jan; 17(1):344-51. PubMed ID: 10458253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of Prophylactic Ondansetron with Intravenous Opioids in Emergency Department Patients: A Prospective Observational Pilot Study.
    Culver MA; Richards EC; Jarrell DH; Edwards CJ
    J Emerg Med; 2017 Nov; 53(5):629-634. PubMed ID: 28987314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation.
    Fox-Geiman MP; Fisher SG; Kiley K; Fletcher-Gonzalez D; Porter N; Stiff P
    Biol Blood Marrow Transplant; 2001; 7(11):596-603. PubMed ID: 11760147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [New, in Austria registered specialty drugs. Zofran (Ondansetron, Glaxo)].
    Erben M
    Wien Klin Wochenschr; 1991; 103(19):594-601. PubMed ID: 1836917
    [No Abstract]   [Full Text] [Related]  

  • 37. [Examination of anti-emetic effect and safety of multiple intravenous doses of ondansetron in patients receiving nonplatinum anti-cancer drugs].
    Nukariya N; Niitani H; Taguchi T; Furue H; Ota K; Tsukagoshi S; Ariyoshi Y; Ikeda M; Akasaka Y; Ohta J
    Gan To Kagaku Ryoho; 1992 Aug; 19(9):1375-85. PubMed ID: 1386978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective evaluation of ondansetron for undifferentiated nausea and vomiting in the prehospital setting.
    Warden CR; Moreno R; Daya M
    Prehosp Emerg Care; 2008; 12(1):87-91. PubMed ID: 18189184
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Combined use of ondansetron and other anti-emetics to control cisplatin-induced nausea and vomiting].
    Zeng WY
    Zhonghua Zhong Liu Za Zhi; 1993 Mar; 15(2):118-21. PubMed ID: 8223120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiemetic activity of ondansetron in cancer patients receiving non-cisplatin chemotherapy.
    Fraschini G
    Semin Oncol; 1992 Aug; 19(4 Suppl 10):41-7. PubMed ID: 1387249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.